A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification

References

• Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol 2010;55:108-33
   PubMed Web of Science ®Google Scholar
• Flach AJ. Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin 2002;42:1-11
   PubMedGoogle Scholar
• Samiy N, Foster CS. The role of nonsteroidal antiinflammatory drugs in ocular inflammation. Int Ophthalmol Clin 1996;36:195-206
   PubMedGoogle Scholar
• Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica 2003;217:89-98
   PubMed Web of Science ®Google Scholar
• Koay P. The emerging roles of topical non-steroidal anti-inflammatory agents in ophthalmology. Br J Ophthalmol 1996;80:480-5
   PubMed Web of Science ®Google Scholar
• Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004;18:790-804
   PubMed Web of Science ®Google Scholar
• Xibrom. Irvine: ISTA Pharmaceuticals, 2010
   Google Scholar
• Donnenfeld ED, Holland EJ, Stewart RH, et al. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation. Ophthalmology 2007;114:1653-62
   PubMed Web of Science ®Google Scholar
• Nevanac. Fort Worth: Alcon Laboratories, 2008
   Google Scholar
• Acular LS. Irvine: Allergan, Inc., 2008
   Google Scholar
• Acuvail. Irvine: Allergan, Inc., 2009
   Google Scholar
• Donnenfeld ED, Perry HD, Wittpenn JR, et al. Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: pharmacokinetic-response curve. J Cataract Refract Surg 2006;32:1474-82
   PubMed Web of Science ®Google Scholar
• Perry HD, Donnenfeld ED. An update on the use of ophthalmic ketorolac tromethamine 0.4%. Expert Opin Pharmacother 2006;7:99-107
   PubMed Web of Science ®Google Scholar
• Price MO, Price FW. Efficacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgery. Curr Med Res Opin 2004;20:2015-19
   PubMed Web of Science ®Google Scholar
• Solomon KD, Donnenfeld ED, Raizman M, et al. Safety and efficacy of ketorolac tromethamine 0.4% ophthalmic solution in post-photorefractive keratectomy patients. J Cataract Refract Surg 2004;30:1653-60
   PubMed Web of Science ®Google Scholar
• Bucci FA Jr, Waterbury LD, Amico LM. Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (acular LS) and nepafenac 0.1% (nevanac) in patients undergoing phacoemulsification. Am J Ophthalmol 2007;144:146-7
   PubMed Web of Science ®Google Scholar
• Bucci FA Jr, Waterbury LD. Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: aqueous drug absorption and prostaglandin E2 levels. J Cataract Refract Surg 2008;34:1509-12
   PubMed Web of Science ®Google Scholar
• Amico LM, Bucci FA Jr, Waterbury LD. Aqueous penetration of ketorolac 0.4% compared with bromfenac 0.09% in cataract patients: peak and trough drug concentations. Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Fort Lauderdale, FL, USA, 2007
   Google Scholar
• Bucci FA Jr, Waterbury LD. Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing. Adv Ther 2009;26:645-50
   PubMed Web of Science ®Google Scholar
• Donnenfeld ED, Nichamin LD, Hardten DR, et al. Twice-daily, preservative-free ketorolac 0.45% for treatment of inflammation and pain after cataract surgery. Am J Ophthalmol 2011;151:420-26
   Google Scholar
• Garrett Q, Simmons PA, Xu S, et al. Carboxymethylcellulose binds to human corneal epithelial cells and is a modulator of corneal epithelial wound healing. Invest Ophthalmol Vis Sci 2007;48:1559-67
   PubMed Web of Science ®Google Scholar
• Bucci FA Jr, Waterbury LD, Evans R, et al. Aqueous PGE2 inhibition of ketorolac tromethamine 0.45%, bromfenac 0.09% and nepafenac 0.1% in patients undergoing phacoemulsification. Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). Fort Lauderdale, FL, USA, 2010
   Google Scholar
• Chandler SP, Henderson BA, Gayton J, et al. Integrated phase 3 clinical trials of bromfenac sodium ophthalmic solution dosed once daily for ocular surgery. American Academy of Ophthalmology. Chicago, 2010
   Google Scholar
• Baranano DE, Kim SJ, Edelhauser HF, et al. Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. Br J Ophthalmol 2009;93:1387-90
   PubMed Web of Science ®Google Scholar
• Bucci Jr FA. Ketorolac versus bromfenac: review of 7 prospective randomized studies comparing PGE2 inhibition and aqueous penetration. ASCRS/ASOA 2011. San Diego: American Society Cataract Refractive Surgery, 2011
   Google Scholar